DaVita (NYSE:DVA) Updates FY24 Earnings Guidance

DaVita (NYSE:DVA) issued an update on its FY24 earnings guidance on Thursday morning. The company provided earnings per share guidance of $9.00-$9.80 for the period, compared to the consensus earnings per share estimate of $9.30.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on DVA. TheStreet upgraded shares of DaVita from a c+ rating to a b- rating in a research note on Wednesday, February 7th. Truist Financial lifted their target price on shares of DaVita from $130.00 to $135.00 and gave the company a hold rating in a research note on Tuesday, February 20th. UBS Group lifted their target price on shares of DaVita from $113.00 to $134.00 and gave the company a buy rating in a research note on Wednesday, February 14th. StockNews.com upgraded shares of DaVita from a buy rating to a strong-buy rating in a research note on Thursday, April 25th. Finally, Barclays assumed coverage on shares of DaVita in a report on Wednesday, March 6th. They issued an equal weight rating and a $133.00 price target for the company. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, DaVita has a consensus rating of Moderate Buy and an average price target of $118.50.

DaVita Price Performance

Shares of DaVita stock traded down $7.79 during midday trading on Friday, reaching $134.45. The company had a trading volume of 2,541,405 shares, compared to its average volume of 628,593. The company has a current ratio of 1.19, a quick ratio of 1.13 and a debt-to-equity ratio of 6.65. The company has a market capitalization of $11.79 billion, a price-to-earnings ratio of 15.28, a price-to-earnings-growth ratio of 1.20 and a beta of 1.04. The stock has a fifty day simple moving average of $133.71 and a 200 day simple moving average of $112.84. DaVita has a 1-year low of $71.51 and a 1-year high of $145.04.

DaVita (NYSE:DVA) last released its earnings results on Thursday, May 2nd. The company reported $2.38 EPS for the quarter, topping analysts’ consensus estimates of $1.95 by $0.43. DaVita had a net margin of 6.61% and a return on equity of 66.59%. The firm had revenue of $3.07 billion during the quarter, compared to analyst estimates of $3.03 billion. During the same quarter in the previous year, the business earned $1.58 EPS. The business’s quarterly revenue was up 6.9% compared to the same quarter last year. As a group, equities research analysts forecast that DaVita will post 9.49 earnings per share for the current year.

Insiders Place Their Bets

In other DaVita news, CEO Javier Rodriguez sold 67,603 shares of DaVita stock in a transaction on Monday, February 26th. The shares were sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the completion of the sale, the chief executive officer now owns 488,697 shares of the company’s stock, valued at approximately $61,629,578.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Javier Rodriguez sold 67,603 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $126.11, for a total value of $8,525,414.33. Following the completion of the transaction, the chief executive officer now owns 488,697 shares of the company’s stock, valued at approximately $61,629,578.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Kathleen Alyce Waters sold 11,285 shares of the business’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $120.73, for a total transaction of $1,362,438.05. Following the completion of the transaction, the insider now directly owns 81,297 shares of the company’s stock, valued at approximately $9,814,986.81. The disclosure for this sale can be found here. In the last 90 days, insiders sold 134,540 shares of company stock valued at $16,551,071. Company insiders own 1.40% of the company’s stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.